Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

BACKGROUND: We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L., Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791835/
https://www.ncbi.nlm.nih.gov/pubmed/26981242
http://dx.doi.org/10.1186/s40425-016-0116-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791835/
https://www.ncbi.nlm.nih.gov/pubmed/26981242
http://dx.doi.org/10.1186/s40425-016-0116-2

Ejemplares similares